SCHEMBL15840696

SCHEMBL15840696

COC(=O)Cc1cc(=O)nc(Nc2nc(C)c3ccccc3n2)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
ALDH1A1 P00352 8/20 0.58
MAPK1 P28482 2/20 0.53
HSD17B10 Q99714 1/20 0.53
ALPL P05186 1/20 0.51
ALPI P09923 1/20 0.51
ALPG P10696 1/20 0.51
AURKA O14965 1/20 0.50
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
PAX8 Q06710 2/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 4/20 0.47
HTT P42858 2/20 0.47
MITF O75030 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 5/20 0.45
CREBBP Q92793 2/20 0.45
STAT3 P40763 2/20 0.44
TDP2 O95551 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495430 0.83 MAPK1 (0.57) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL15840751 0.76 MAPT (0.62) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL880408 0.76 MAPT (0.71) MAPTALDH1A1HSD17B10LMNASMN1; SMN2
SCHEMBL31457428 0.71 SMN1; SMN2 (0.48) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL31457426 0.71 SMN1; SMN2 (0.48) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL14942692 0.70 USP2 (0.45) MAPTALDH1A1MAPK1HSD17B10LMNA
SCHEMBL31457434 0.70 HSD17B10 (0.52) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL15840695 0.69 MAPT (0.74) MAPTALDH1A1MAPK1HSD17B10ALPL
SCHEMBL13310315 0.69 MAPK1 (0.54) MAPTALDH1A1MAPK1HSD17B10LMNA
SCHEMBL23657938 0.69 MAPK1 (0.57) MAPTALDH1A1MAPK1HSD17B10ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885MAPK1 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.